cidofovir 1% topical ointment — Competitive Intelligence Brief

cidofovir 1% topical ointment (cidofovir 1% topical ointment) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside analogue. Area: Infectious Diseases.

phase 3 Nucleoside analogue DNA polymerase Infectious Diseases Small molecule

Target snapshot

cidofovir 1% topical ointment (cidofovir 1% topical ointment) — Hospital Universitari Vall d'Hebron Research Institute. Cidofovir is an antiviral medication that works by inhibiting viral DNA polymerase.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
cidofovir 1% topical ointment TARGET	cidofovir 1% topical ointment	Hospital Universitari Vall d'Hebron Research Institute	phase 3	Nucleoside analogue	DNA polymerase
Hepsera	ADEFOVIR DIPIVOXIL	Gilead Sciences	marketed	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor	DNA polymerase subunit gamma-1	2002-01-01
Gemzar	gemcitabine	Accord Hlthcare	marketed	Nucleoside Metabolic Inhibitor	DNA polymerase (alpha/delta/epsilon)	1996-01-01
VALACYCLOVIR	VALACYCLOVIR		marketed	Nucleoside analogue	Viral DNA polymerase	1995-01-01
Cytarabine	Cytarabine	Nippon Shinyaku Co., Ltd.	marketed	Antimetabolite	DNA polymerase	1969-01-01
Valacyclovir (ZELITREX)	Valacyclovir (ZELITREX)	Assistance Publique - Hôpitaux de Paris	marketed	Nucleoside analog antiviral	Viral DNA polymerase (herpesvirus)
Fludarabine (FLU)	Fludarabine (FLU)	Nanfang Hospital, Southern Medical University	marketed	Purine nucleoside analog	Ribonucleotide reductase, DNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside analogue class)

1. · 1 drug in this class
2. Hospital Universitari Vall d'Hebron Research Institute · 1 drug in this class